Sanofi Targets €25B Dupixent Goal and Expands M&A Hunt

Sanofi (NASDAQ: SNY) has updated its long-term commercial targets, elevating its 2030 Dupixent sales goal to €25 billion on Sunday, September 20, 2026, while positioning its balance sheet for an expanded M&A pipeline.

### Money Play - **$SNY+WL**: Watch for upcoming announcements regarding potential additions to its core specialty care and rare disease portfolios, as management weighs both large transformative transactions and smaller tuck-in acquisitions to offset future patent cliffs.

## Catalyst Analysis: [Primary Driver] The upward revision for Dupixent is underpinned by strong commercial momentum, recording greater than 30% growth in the first half of the year, alongside expansion into pediatric populations and underpenetrated therapeutic areas like chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

## Technical Analysis & Key Risk Watch

With Sanofi actively preparing for the loss of exclusivity for Dupixent in the early part of the next decade, management is prioritizing R&D productivity and broader business-development execution. Key new-launch contributors such as AYVAKIT, ALTUVIIIO, and SARCLISA anchor the company's separate €10 billion new-launch ambition.

## Impact on [Sector / Related Tickers] The biopharmaceutical sector faces ongoing patent expiration cycles, forcing major market participants like Sanofi to aggressively scout external science and commercial-stage assets across immunology, rare diseases, and vaccines.